This site is intended for healthcare professionals

Digital illustration of male genitalia with the prostate enlarged and highlighted in red

Prostate Cancer

Containing dedicated Learning Zones, guidelines, trials, journals and news

Last updated: 5th Mar 2024

Prostate cancer most often develops from prostatic intraepithelial neoplasia (PIN) in the prostate gland and can be described as localised, locally advanced or advanced (metastatic). Symptoms may include genito-urinary symptoms such as poor urinary stream and erectile dysfunction, or bone pain in cases where the disease has spread to the bones.

Prostate cancer is considered a slow growing cancer and is driven by the androgen axis. Subsequently, treatment for hormone sensitive prostate cancer (HSPC) revolves around androgen deprivation therapy (ADT) alongside radiation therapy and chemotherapy.

Digital illustration of male genitalia with the prostate enlarged and highlighted in red

Independent, grant-supported education for prostate cancer

Resources created with our funding partners

DNA AI generated image

Podcast series: Molecular biomarker testing for prostate cancer

Listen to experts discuss the latest on molecular biomarker testing for prostate cancer, in this podcast series.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Related news and insights

Darolutamide meets primary endpoint in phase III ARANOTE trial in men with metastatic hormone-sensitive prostate cancer

The Phase III ARANOTE trial, investigating darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of rPFS.(radiological progression-free survival)

2 mins

Merck Inc., announces exercise of option providing Merck Inc., with global exclusive rights to opevesostat for the treatment of metastatic castration-resistant prostate cancer.

Merck Inc. known as MSD outside of the United States and Canada, and Orion Corporation announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck

1 min

Clinical trial update on treatments for mCRPC

A summary of selected clinical trial data and approvals for metastatic castration-resistant prostate cancer (mCRPC) treatments from 2020 to 2023.

4 min

See all news

Related Journal Articles

Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers

1 mins

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

1 mins

A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery.

1 mins

Emerging therapeutic targets for patients with advanced prostate cancer.

1 mins

10-year outcomes after monitoring, surgery, or radiotherapy for localised prostate cancer

1 mins

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.

1 mins

Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis.

1 mins

Alternative splicing in prostate cancer.

1 mins

Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.

1 mins

Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer.

1 mins

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

1 mins

Urinary biomarkers of prostate cancer.

1 mins

The microbiome in prostate inflammation and prostate cancer.

1 mins

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

1 mins

Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

1 mins

PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.

1 mins

Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer.

1 mins

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

2 mins

The use of PET/CT in prostate cancer.

1 mins

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

1 mins

Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials

1 mins

Biological Evolution of Castration-resistant Prostate Cancer.

1 mins

Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

1 mins

Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose-response meta-analysis.

1 mins

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer

1 mins

Abiraterone acetate in the treatment of prostate cancer.

1 mins

Association between gallbladder stone disease and prostate cancer: A nationwide population-based study.

1 mins

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

2 mins

Prostate cancer diagnosis on repeat magnetic resonance imaging-transrectal ultrasound fusion biopsy of benign lesions: recommendations for repeat sampling.

1 mins

Genomics of lethal prostate cancer at diagnosis and castration-resistance.

1 mins

Related Guidelines

EAU Guidelines on Prostate Cancer

The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical professionals in the evidence-based management of PCa.

1 mins

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Prostate cancer is reported as the second most common cancer in men.

1 min

Prostate cancer: diagnosis and management

This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment.

1 min

See all guidelines

Related Clinical Trials

Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer

3 mins